{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:58:15Z","timestamp":1790398695889,"version":"4.1.0"},"reference-count":171,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.autrev.2021.102832","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T07:51:01Z","timestamp":1618559461000},"page":"102832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Combination therapy in inflammatory bowel disease \u2013 from traditional immunosuppressors towards the new paradigm of dual targeted therapy"],"prefix":"10.1016","volume":"20","author":[{"given":"Giuseppe","family":"Privitera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Onali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Petito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Scaldaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gasbarrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2021.102832_bb0005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cgh.2019.07.005","article-title":"Ulcerative colitis and Crohn\u2019s disease have similar burden and goals for treatment","author":"Le Berre","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102832_bb0010","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first european evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease","volume":"10","author":"Harbord","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10.1016\/j.autrev.2021.102832_bb0015","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/ibd\/izz105","article-title":"The impact of spondyloarthritis and joint symptoms on health-related quality of life and fatigue in IBD patients. Results from a population-based inception cohort (20-year follow-up in the Ibsen study)","volume":"26","author":"Ossum","year":"2020","journal-title":"Inflamm Bowel Dis"},{"issue":"46","key":"10.1016\/j.autrev.2021.102832_bb0020","doi-asserted-by":"crossref","first-page":"8182","DOI":"10.3748\/wjg.v23.i46.8182","article-title":"Prevalence of-and risk factors for work disability in Dutch patients with inflammatory bowel disease","volume":"23","author":"Spekhorst","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"9","key":"10.1016\/j.autrev.2021.102832_bb0025","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.autrev.2021.102832_bb0030","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: Medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"7","key":"10.1016\/j.autrev.2021.102832_bb0035","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: Current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2021.102832_bb0040","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.autrev.2019.03.002","article-title":"Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review","author":"Jeong","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102832_bb0045","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Manteniance infliximab in Crohn\u2019s disease: The ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.autrev.2021.102832_bb0050","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.autrev.2021.102832_bb0055","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2016","journal-title":"Gut"},{"issue":"13","key":"10.1016\/j.autrev.2021.102832_bb0060","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.autrev.2021.102832_bb0065","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.autrev.2021.102832_bb0070","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2021.102832_bb0075","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ecco-jcc\/jjx143","article-title":"Vedolizumab in IBD-lessons from real-world experience; a systematic review and pooled analysis","volume":"12","author":"Engel","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"9","key":"10.1016\/j.autrev.2021.102832_bb0080","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn\u2019s disease: Results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.autrev.2021.102832_bb0085","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: The CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.autrev.2021.102832_bb0090","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2021.102832_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: An updated network meta-analysis","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2021.102832_bb0100","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/apt.14852","article-title":"Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn\u2019s disease","author":"Singh","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.autrev.2021.102832_bb0105","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/ibd\/izz001","article-title":"Real-world pattern of biologic use in patients with inflammatory bowel disease: Treatment persistence, switching, and importance of concurrent immunosuppressive therapy","volume":"25","author":"Chen","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.autrev.2021.102832_bb0110","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cei.12742","article-title":"From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals","volume":"184","author":"Gunn","year":"2016","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2021.102832_bb0115","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","article-title":"Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis","volume":"149","author":"Brandse","year":"2015","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.autrev.2021.102832_bb0120","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"issue":"9240","key":"10.1016\/j.autrev.2021.102832_bb0125","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0140-6736(00)02871-3","article-title":"Mechanisms in failure of infliximab for Crohn\u2019s disease","volume":"356","author":"Nikolaus","year":"2000","journal-title":"Lancet (London, England)"},{"issue":"10","key":"10.1016\/j.autrev.2021.102832_bb0130","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.cgh.2012.06.032","article-title":"Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease","volume":"10","author":"Ord\u00e1s","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.autrev.2021.102832_bb0135","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy","volume":"171","author":"Palmer","year":"2017","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.autrev.2021.102832_bb0140","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.autrev.2021.102832_bb0145","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/mi.2016.65","article-title":"The ATG16L1 risk allele associated with Crohn\u2019s disease results in a Rac1-dependent defect in dendritic cell migration that is corrected by thiopurines","volume":"10","author":"Wildenberg","year":"2017","journal-title":"Mucosal Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2021.102832_bb0150","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2010.10.008","article-title":"AntiTumor necrosis factor-\u03b1 antibodies induce regulatory macrophages in an Fc region-dependent manner","volume":"140","author":"Vos","year":"2011","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.autrev.2021.102832_bb0155","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ibd.21818","article-title":"Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro","volume":"18","author":"Vos","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2021.102832_bb0160","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","article-title":"Optimizing anti-TNF treatments in inflammatory bowel disease","author":"Ben-Horin","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102832_bb0165","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrgastro.2013.253","article-title":"Tailoring anti-TNF therapy in IBD: Drug levels and disease activity","author":"Ben-Horin","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"15","key":"10.1016\/j.autrev.2021.102832_bb0170","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.autrev.2021.102832_bb0175","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.cgh.2018.09.033","article-title":"Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a post hoc analysis","volume":"17","author":"Colombel","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.autrev.2021.102832_bb0180","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2010.212712","article-title":"Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy","volume":"59","author":"Sokol","year":"2010","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.autrev.2021.102832_bb0185","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1097\/MIB.0000000000000208","article-title":"Influence of combination therapy with immune modulators on anti-TNF trough levels and antibodies in patients with IBD","volume":"20","author":"Van Schaik","year":"2014","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"10.1016\/j.autrev.2021.102832_bb0190","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/apt.13808","article-title":"Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn\u2019s disease","volume":"44","author":"Cosnes","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.autrev.2021.102832_bb0195","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.cgh.2018.11.003","article-title":"Upfront combination therapy, compared with monotherapy, for patients not previously treated with a biologic agent associates with reduced risk of inflammatory bowel disease-related complications in a population-based cohort study","volume":"17","author":"Targownik","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2021.102832_bb0200","first-page":"1","article-title":"Combined biologic and immunomodulatory therapy is superior to monotherapy for decreasing the risk of inflammatory bowel disease-related complications","author":"Targownik","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"5","key":"10.1016\/j.autrev.2021.102832_bb0205","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.autrev.2021.102832_bb0210","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn\u2019s disease","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.autrev.2021.102832_bb0215","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.autrev.2021.102832_bb0220","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/apt.13102","article-title":"Systematic review with meta-analysis: Infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis","volume":"41","author":"Christophorou","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.autrev.2021.102832_bb0225","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1097\/MIB.0000000000000115","article-title":"Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis","volume":"20","author":"Armuzzi","year":"2014","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.autrev.2021.102832_bb0230","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/jgh.12517","article-title":"Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis","volume":"29","author":"Hayes","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.autrev.2021.102832_bb0235","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/apt.14125","article-title":"The benefit of combination therapy depends on disease phenotype and duration in Crohn\u2019s disease","volume":"46","author":"Ananthakrishnan","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.autrev.2021.102832_bb0240","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/MIB.0b013e3182802909","article-title":"Infliximab in steroid-dependent ulcerative colitis: Effectiveness and predictors of clinical and endoscopic remission","volume":"19","author":"Armuzzi","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2021.102832_bb0245","first-page":"1","article-title":"Combination therapy in inflammatory bowel disease patients: do we need to maximize the dose of azathioprine?","author":"Arieira","year":"2020","journal-title":"Scand J Gastroenterol"},{"issue":"8","key":"10.1016\/j.autrev.2021.102832_bb0250","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.dld.2019.05.001","article-title":"Positive pharmacokinetic effect of azathioprine co-medication on infliximab trough levels is dose-dependent","volume":"51","author":"Polakovicova","year":"2019","journal-title":"Dig Liver Dis"},{"issue":"4","key":"10.1016\/j.autrev.2021.102832_bb0255","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: Management of Crohn\u2019s disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102832_bb0260","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.gastro.2013.11.024","article-title":"Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn\u2019s disease","volume":"146","author":"Feagan","year":"2014","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.autrev.2021.102832_bb0265","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/ecco-jcc\/jjw152","article-title":"Adalimumab monotherapy and a combination with azathioprine for Crohn\u2019s disease: A prospective, randomized trial","volume":"10","author":"Matsumoto","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"5","key":"10.1016\/j.autrev.2021.102832_bb0270","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1053\/j.gastro.2009.07.062","article-title":"Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn\u2019s disease","volume":"137","author":"Karmiris","year":"2009","journal-title":"Gastroenterology"},{"issue":"11\u201312","key":"10.1016\/j.autrev.2021.102832_bb0275","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/apt.12076","article-title":"Does co-treatment with immunosuppressors improve outcome in patients with Crohn\u2019s disease treated with adalimumab?","volume":"36","author":"Reenaers","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.autrev.2021.102832_bb0280","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/MIB.0000000000001183","article-title":"Thiopurines dosed to a therapeutic 6-thioguanine level in combination with adalimumab are more effective than subtherapeutic thiopurine-based combination therapy or adalimumab monotherapy during induction and maintenance in patients with long-standing Cro","volume":"23","author":"Kariyawasam","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"10.1016\/j.autrev.2021.102832_bb0285","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.crohns.2014.07.003","article-title":"Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn\u2019s disease: A systematic review and meta-analysis","volume":"8","author":"Kopylov","year":"2014","journal-title":"J Crohns Colitis"},{"issue":"8","key":"10.1016\/j.autrev.2021.102832_bb0290","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1097\/MIB.0000000000001203","article-title":"Systematic review and meta-analysis: adalimumab monotherapy versus combination therapy with immunomodulators for induction and maintenance of remission and response in patients with Crohn\u2019s disease","volume":"23","author":"Chalhoub","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.autrev.2021.102832_bb0295","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/apt.13838","article-title":"Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn\u2019s disease or ulcerative colitis who had failed conventional therapy","volume":"45","author":"Colombel","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.autrev.2021.102832_bb0300","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/gutjnl-2014-307126","article-title":"Systematic review: Monotherapy with antitumour necrosis factor \u03b1 agents versus combination therapy with an immunosuppressive for IBD","volume":"63","author":"Dulai","year":"2014","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.autrev.2021.102832_bb0305","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in Crohn\u2019s disease treated with scheduled infliximab maintenance: A randomized trial","volume":"134","author":"Van Assche","year":"2008","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.autrev.2021.102832_bb0310","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.cgh.2014.07.027","article-title":"Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with crohn\u2019s disease","volume":"13","author":"Drobne","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.autrev.2021.102832_bb0315","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/apt.14106","article-title":"Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial","volume":"46","author":"Roblin","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2021.102832_bb0320","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/apt.14368","article-title":"Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases","author":"Mitrev","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.autrev.2021.102832_bb0325","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1136\/gutjnl-2019-319758","article-title":"Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: A prospective randomised trial","volume":"69","author":"Roblin","year":"2020","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.autrev.2021.102832_bb0330","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/ibd\/izx010","article-title":"The addition of an immunosuppressant after loss of response to anti-TNF\u03b1 monotherapy in inflammatory bowel disease: A 2-year study","volume":"24","author":"Macaluso","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2021.102832_bb0335","article-title":"Adding thiopurine after loss of response to infliximab versus early combination in treating Crohn\u2019s disease: A retrospective study","volume":"0123456789","author":"Zeze","year":"2020","journal-title":"Dig Dis Sci"},{"issue":"8","key":"10.1016\/j.autrev.2021.102832_bb0340","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/apt.13994","article-title":"Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease","volume":"45","author":"Strik","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.autrev.2021.102832_bb0345","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/apt.13862","article-title":"Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab","volume":"45","author":"Ungar","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.autrev.2021.102832_bb0350","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.cgh.2012.10.020","article-title":"Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease","volume":"11","author":"Ben-Horin","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.autrev.2021.102832_bb0355","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1111\/jgh.12263","article-title":"Addition of thiopurines can recapture response in patients with Crohn\u2019s disease who have lost response to anti-tumor necrosis factor monotherapy","volume":"28","author":"Ong","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.autrev.2021.102832_bb0360","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/ecco-jcc\/jjw008","article-title":"Anti-TNF monotherapy for Crohn\u2019s disease: A 13-year multicentre experience","volume":"10","author":"Peyrin-Biroulet","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"8","key":"10.1016\/j.autrev.2021.102832_bb0365","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.autrev.2021.102832_bb0370","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2021.102832_bb0375","article-title":"No benefit of concomitant immunomodulator therapy on efficacy of biologics that are not tumor necrosis factor antagonists in patients with inflammatory bowel diseases: a meta-analysis","author":"Yzet","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.autrev.2021.102832_bb0380","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/apt.13243","article-title":"Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn\u2019s disease","volume":"42","author":"Rosario","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"6\u20137","key":"10.1016\/j.autrev.2021.102832_bb0385","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1080\/00365521.2017.1304987","article-title":"Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)","volume":"52","author":"Eriksson","year":"2017","journal-title":"Scand J Gastroenterol"},{"issue":"8","key":"10.1016\/j.autrev.2021.102832_bb0390","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/ajg.2016.236","article-title":"The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn\u2019s disease: Results from the US VICTORY consortium","volume":"111","author":"Dulai","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.autrev.2021.102832_bb0395","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.cgh.2017.03.032","article-title":"Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn\u2019s disease","volume":"15","author":"Battat","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2021.102832_bb0400","article-title":"Combination therapy does not improve rate of clinical or endoscopic remission in patients with inflammatory bowel diseases treated with vedolizumab or ustekinumab","author":"Hu","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.autrev.2021.102832_bb0405","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1007\/s10620-017-4549-3","article-title":"Predictors of clinical response and remission at 1 year among a multicenter cohort of patients with inflammatory bowel disease treated with vedolizumab","volume":"62","author":"Allegretti","year":"2017","journal-title":"Dig Dis Sci"},{"issue":"7","key":"10.1016\/j.autrev.2021.102832_bb0410","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/apt.14541","article-title":"Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab","volume":"47","author":"Macaluso","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2021.102832_bb0415","unstructured":"Accessdata.fda.gov. 2021. [online] Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203214s018lbl.pdf [Accessed 03 February 2021]."},{"issue":"5","key":"10.1016\/j.autrev.2021.102832_bb0420","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/ecco-jcc\/jjx179","article-title":"New promising combo therapy in inflammatory bowel diseases refractory to anti-TNF agents: Cyclosporine plus vedolizumab","volume":"12","author":"Sz\u00e1nt\u00f3","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"3","key":"10.1016\/j.autrev.2021.102832_bb0425","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.cgh.2018.04.060","article-title":"Safety and efficacy of combination treatment with calcineurin inhibitors and vedolizumab in patients with refractory inflammatory bowel disease","volume":"17","author":"Christensen","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102832_bb0430","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.cgh.2018.08.081","article-title":"Efficacy and safety of induction therapy with calcineurin inhibitors in combination with vedolizumab in patients with refractory ulcerative colitis","volume":"17","author":"Pellet","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.autrev.2021.102832_bb0435","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/apt.15616","article-title":"Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis","volume":"51","author":"Ollech","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.autrev.2021.102832_bb0440","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/apt.15896","article-title":"Letter: ciclosporin and vedolizumab for steroid-refractory ulcerative colitis","volume":"52","author":"Res\u00e1l","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2021.102832_bb0445","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820954112","article-title":"Successful cyclosporin and ustekinumab combination therapy in a patient with severe steroid-refractory ulcerative colitis","volume":"13","author":"Ganzleben","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.autrev.2021.102832_bb0450","author":"Clinical Trials.Gov"},{"key":"10.1016\/j.autrev.2021.102832_bb0455","author":"Clinical Trials.Gov"},{"key":"10.1016\/j.autrev.2021.102832_bb0460","author":"Clinical Trials.Gov"},{"key":"10.1016\/j.autrev.2021.102832_bb0465","author":"Clinical Trials.Gov"},{"issue":"5","key":"10.1016\/j.autrev.2021.102832_bb0470","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/ibd\/izx110","article-title":"Combining anti-TNF-\u03b1 and vedolizumab in the treatment of inflammatory bowel disease: a case series","volume":"24","author":"Buer","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2021.102832_bb0475","article-title":"Combination biologic therapy in inflammatory bowel disease: Experience from a Tertiary Care Center","author":"Kwapisz","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2021.102832_bb0480","doi-asserted-by":"crossref","DOI":"10.1111\/1751-2980.12867","article-title":"The use of combination biologic or small molecule therapy in inflammatory bowel disease: A retrospective cohort study","author":"Glassner","year":"2020","journal-title":"J Dig Dis"},{"key":"10.1016\/j.autrev.2021.102832_bb0485","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/apt.15719","article-title":"Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn\u2019s disease","author":"Yang","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2021.102832_bb0490","article-title":"Dual targeted therapy: a possible option for the management of refractory inflammatory bowel disease","author":"Privitera","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"5","key":"10.1016\/j.autrev.2021.102832_bb0495","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/ajg.2016.66","article-title":"Ustekinumab and anti-TNF combination therapy in patients with inflammatory bowel disease","volume":"111","author":"Yzet","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.autrev.2021.102832_bb0500","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40272-020-00396-1","article-title":"Combination of biological agents in moderate to severe pediatric inflammatory bowel disease: A case series and review of the literature","volume":"22","author":"Olbj\u00f8rn","year":"2020","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.autrev.2021.102832_bb0505","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1046\/j.1365-2036.2001.01060.x","article-title":"Review article: The limitations of corticosteroid therapy in crohn\u2019s disease","author":"Rutgeerts","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.autrev.2021.102832_bb0510","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ibd.20014","article-title":"Safety and tolerability of concurrent natalizumab treatment for patients with Crohn\u2019s disease not in remission while receiving infliximab","volume":"13","author":"Sands","year":"2007","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"10.1016\/j.autrev.2021.102832_bb0515","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: A mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.autrev.2021.102832_bb0520","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.autrev.2018.07.014","article-title":"Bispecific antibodies: The next generation of targeted inflammatory bowel disease therapies","volume":"18","author":"Peyrin-Biroulet","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2021.102832_bb0525","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40259-019-00400-2","article-title":"Bispecific antibodies for autoimmune and inflammatory diseases: Clinical progress to date","volume":"34","author":"Zhao","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.autrev.2021.102832_bb0530","first-page":"666","article-title":"Bispecific antibody pipeline moves beyond oncology","author":"Mullard","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.autrev.2021.102832_bb0535","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative molecular formats and therapeutic applications for bispecific antibodies","author":"Spiess","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.autrev.2021.102832_bb0540","author":"Clinical Trials.Gov"},{"issue":"11","key":"10.1016\/j.autrev.2021.102832_bb0545","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.147.11.3815","article-title":"IL-10 inhibits cytokine production by activated macrophages","volume":"147","author":"Fiorentino","year":"1991","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2021.102832_bb0550","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.151.3.1224","article-title":"IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression","volume":"151","author":"Ding","year":"1993","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2021.102832_bb0555","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.150.11.4754","article-title":"Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation","volume":"150","author":"de Waal Malefyt","year":"1993","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2021.102832_bb0560","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.154.10.5492","article-title":"A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses","volume":"154","author":"Chernoff","year":"1995","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2021.102832_bb0565","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1053\/gast.2000.20229","article-title":"Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn\u2019s disease","volume":"119","author":"Fedorak","year":"2000","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.autrev.2021.102832_bb0570","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1053\/gast.2000.20196","article-title":"Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn\u2019s disease","volume":"119","author":"Schreiber","year":"2000","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.autrev.2021.102832_bb0575","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/gut.49.1.42","article-title":"Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn\u2019s disease","volume":"49","author":"Colombel","year":"2001","journal-title":"Gut"},{"issue":"MAY","key":"10.1016\/j.autrev.2021.102832_bb0580","first-page":"1","article-title":"APVO210: A Bispecific Anti-CD86-IL-10 Fusion Protein (ADAPTIRTM) to induce antigen-specific T regulatory type 1 cells","volume":"9","author":"Pellerin","year":"2018","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2021.102832_bb0585","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1073\/pnas.89.5.1890","article-title":"Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes","volume":"89","author":"Rousset","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.autrev.2021.102832_bb0590","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.4049\/jimmunol.160.7.3188","article-title":"Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells","volume":"160","author":"Groux","year":"1998","journal-title":"J Immunol"},{"issue":"9613","key":"10.1016\/j.autrev.2021.102832_bb0595","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn\u2019s disease: an open randomised trial","volume":"371","author":"D\u2019Haens","year":"2008","journal-title":"Lancet"},{"issue":"10006","key":"10.1016\/j.autrev.2021.102832_bb0600","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(15)00068-9","article-title":"Early combined immunosuppression for the management of Crohn\u2019s disease (REACT): A cluster randomised controlled trial","volume":"386","author":"Khanna","year":"2015","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.autrev.2021.102832_bb0605","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.cgh.2015.06.034","article-title":"Effects of concomitant immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn\u2019s disease: A meta-analysis of placebo-controlled trials","volume":"13","author":"Jones","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.autrev.2021.102832_bb0610","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.autrev.2021.102832_bb0615","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cgh.2015.02.017","article-title":"Effectiveness and safety of immunomodulators with anti-tumor necrosis factor therapy in crohn\u2019s disease","volume":"13","author":"Osterman","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2021.102832_bb0620","first-page":"1","article-title":"Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and\/or thiopurines in patients with inflammatory bowel disease","author":"Chupin","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.autrev.2021.102832_bb0625","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2013.441","article-title":"Drug therapies and the risk of malignancy in crohn\u2019s disease: Results from the TREATTM registry","volume":"109","author":"Lichtenstein","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.autrev.2021.102832_bb0630","first-page":"680","article-title":"Five-year safety data from ENCORE, a European Observational Safety Registry for adults with Crohn\u2019s disease treated with infliximab [Remicade\u00ae] or conventional therapy","volume":"11","author":"D\u2019Haens","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"6","key":"10.1016\/j.autrev.2021.102832_bb0635","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/s41395-018-0098-4","article-title":"Lymphoma risk and overall safety profile of adalimumab in patients with Crohn\u2019s disease with up to 6 years of follow-up in the Pyramid Registry","volume":"113","author":"D\u2019Haens","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.autrev.2021.102832_bb0640","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.12.025","article-title":"Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn\u2019s disease","volume":"146","author":"Osterman","year":"2014","journal-title":"Gastroenterology"},{"issue":"9701","key":"10.1016\/j.autrev.2021.102832_bb0645","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.autrev.2021.102832_bb0650","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.autrev.2021.102832_bb0655","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.gastro.2016.03.037","article-title":"Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: A systematic review and meta-analysis","volume":"151","author":"Shelton","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2021.102832_bb0660","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1517\/14740338.2015.1083974","article-title":"The safety of calcineurin inhibitors for kidney-transplant patients","author":"Malvezzi","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"10.1016\/j.autrev.2021.102832_bb0665","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.cgh.2018.02.024","article-title":"Combining biologics in inflammatory bowel disease and other immune mediated inflammatory disorders","volume":"16","author":"Hirten","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.autrev.2021.102832_bb0670","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/00365521.2019.1597159","article-title":"Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis","volume":"54","author":"Ribaldone","year":"2019","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"10.1016\/j.autrev.2021.102832_bb0675","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","article-title":"Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease","volume":"141","author":"Peyrin-Biroulet","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2021.102832_bb0680","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.crohns.2009.02.010","article-title":"European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","author":"Rahier","year":"2009","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.autrev.2021.102832_bb0685","doi-asserted-by":"crossref","DOI":"10.1177\/2050640620929133","article-title":"Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre","author":"Scaldaferri","year":"2020","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.autrev.2021.102832_bb0690","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41575-020-0294-8","article-title":"Management of IBD during the COVID-19 outbreak: resetting clinical priorities","author":"Danese","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2021.102832_bb0695","article-title":"The management of inflammatory bowel diseases in the era of COVID-19 pandemic: When \u201cnon-urgent\u201d does not mean \u201cdeferrable.\u201d","author":"Pugliese","year":"2020","journal-title":"Int J Pharm"},{"key":"10.1016\/j.autrev.2021.102832_bb0700","series-title":"How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion","author":"Sarzi-Puttini","year":"2020"},{"issue":"9","key":"10.1016\/j.autrev.2021.102832_bb0705","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/ibd\/izaa181","article-title":"The thrilling journey of SARS-CoV-2 into the intestine: From pathogenesis to future clinical implications","volume":"26","author":"Scaldaferri","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2021.102832_bb0710","first-page":"1","article-title":"Inflammatory bowel disease Effect of IBD medications on COVID-19 outcomes: results from an international registry","author":"Ungaro","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2021.102832_bb0715","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izaa275","article-title":"SARS-CoV-2 infection and dual-biologic therapy for Crohn\u2019s disease","author":"Dimopulos","year":"2020","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.autrev.2021.102832_bb0720","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/apt.16271","article-title":"Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy","volume":"53","author":"Privitera","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2021.102832_bb0725","doi-asserted-by":"crossref","DOI":"10.1177\/1756283X17750355","article-title":"Immunogenicity of biologics in inflammatory bowel disease","author":"Vermeire","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"issue":"8","key":"10.1016\/j.autrev.2021.102832_bb0730","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/gutjnl-2013-305259","article-title":"The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab","volume":"63","author":"Ungar","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2021.102832_bb0735","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/ajg.2012.333","article-title":"Decreasing colectomy rates for ulcerative colitis: A population-based time trend study","author":"Kaplan","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.autrev.2021.102832_bb0740","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","article-title":"Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial","volume":"1","author":"Williams","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.autrev.2021.102832_bb0745","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/ajg.2016.7","article-title":"Systematic review and meta-analysis: Infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids","volume":"111","author":"Narula","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"January","key":"10.1016\/j.autrev.2021.102832_bb0750","article-title":"Comparable long-term outcomes of cyclosporine and infliximab in patients with steroid-refractory acute severe ulcerative colitis: A meta-analysis","volume":"6","author":"Szemes","year":"2020","journal-title":"Front Med"},{"issue":"6","key":"10.1016\/j.autrev.2021.102832_bb0755","first-page":"963","article-title":"Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease","volume":"58","author":"Dubash","year":"2019","journal-title":"Rheumatol (United Kingdom)"},{"issue":"6","key":"10.1016\/j.autrev.2021.102832_bb0760","first-page":"1111","article-title":"Comment on: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease","volume":"58","author":"Alivernini","year":"2019","journal-title":"Rheumatol (United Kingdom)"},{"issue":"10","key":"10.1016\/j.autrev.2021.102832_bb0765","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/acr.24025","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2021.102832_bb0770","first-page":"1","article-title":"A systematic review and network meta-analysis of current and investigational treatments for active ankylosing spondylitis","author":"Deodhar","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2021.102832_bb0775","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1080\/17512433.2018.1548277","article-title":"Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis","author":"Stiff","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.autrev.2021.102832_bb0780","doi-asserted-by":"crossref","DOI":"10.1177\/1744806918762205","article-title":"Quantitative evaluation to efficacy and safety of therapies for psoriasis: A network meta-analysis","volume":"14","author":"Lv","year":"2018","journal-title":"Mol Pain"},{"key":"10.1016\/j.autrev.2021.102832_bb0785","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.intimp.2018.06.020","article-title":"Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials","author":"Cui","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.autrev.2021.102832_bb0790","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/1346-8138.14096","article-title":"Safety of biologics in psoriasis","author":"Kamata","year":"2018","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2021.102832_bb0795","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/03007995.2019.1673581","article-title":"Real-word incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors","volume":"36","author":"Pugliese","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"10.1016\/j.autrev.2021.102832_bb0800","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.13352","article-title":"Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study","volume":"42","author":"Pugliese","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2021.102832_bb0805","first-page":"814","article-title":"Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn\u2019s disease","author":"Schmitt","year":"2018","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.autrev.2021.102832_bb0810","first-page":"627","article-title":"Combination of biologic agents in the management of severe refractory Crohn\u2019s disease: A case report of concomitant treatment with vedolizumab and adalimumab","volume":"73","author":"Afzali","year":"2014","journal-title":"Am J Econ Sociol"},{"issue":"10","key":"10.1016\/j.autrev.2021.102832_bb0815","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/ajg.2017.242","article-title":"Long-term combination therapy with anti-TNF plus vedolizumab induces and maintains remission in therapy-refractory ulcerative colitis","volume":"112","author":"Fischer","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2021.102832_bb0820","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/5264216","article-title":"Ustekinumab and vedolizumab dual biologic therapy in the treatment of Crohn\u2019s disease","volume":"2017","author":"Liu","year":"2017","journal-title":"Case Rep Med"},{"issue":"10","key":"10.1016\/j.autrev.2021.102832_bb0825","doi-asserted-by":"crossref","DOI":"10.1097\/MIB.0000000000001232","article-title":"Efficacy of combination vedolizumab and ustekinumab for refractory Crohn\u2019s disease","volume":"23","author":"Huff-Hardy","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.autrev.2021.102832_bb0830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjgast-2018-000243","article-title":"Safety of dual biological therapy in Crohn\u2019s disease: A case series of vedolizumab in combination with other biologics","volume":"5","author":"Mao","year":"2018","journal-title":"BMJ Open Gastroenterol"},{"issue":"7","key":"10.1016\/j.autrev.2021.102832_bb0835","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1093\/ibd\/izaa092","article-title":"Double biologic therapy for refractory stricturing Crohn\u2019s disease: A successful case of deep remission with ustekinumab and vedolizumab","volume":"26","author":"Elmoursi","year":"2020","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.1016\/j.autrev.2021.102832_bb0840","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/apt.15891","article-title":"Letter: combination of biologics in inflammatory bowel diseases","volume":"52","author":"Fumery","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.autrev.2021.102832_bb0845","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/ecco-jcc\/jjx142","article-title":"Co-treatment with golimumab and vedolizumab to treat severe UC and associated spondyloarthropathy","volume":"12","author":"Roblin","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"4","key":"10.1016\/j.autrev.2021.102832_bb0850","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.cgh.2018.08.017","article-title":"Combination therapy with vedolizumab and tofacitinib in a patient with ulcerative colitis and spondyloarthropathy","volume":"17","author":"Le Berre","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2021.102832_bb0855","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1097\/MEG.0000000000001919","article-title":"Landmarks for dual biological therapy in inflammatory bowel disease: Lesson from two case reports of vedolizumab in combination with ustekinumab","author":"Biscaglia","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722100104X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722100104X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:22:13Z","timestamp":1761600133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156899722100104X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":171,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S156899722100104X"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102832","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination therapy in inflammatory bowel disease \u2013 from traditional immunosuppressors towards the new paradigm of dual targeted therapy","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102832","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102832"}}